Trial reportBMC endocrine disorders2026
Virtual care for young adults with type 1 diabetes: a 12-month follow-up of a wait-list randomized controlled trial.
Trial report in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDigital tools are increasingly used in diabetes care, but their long-term effectiveness remains uncertain. A previous randomized controlled trial (RCT) demonstrated promising effects on perceived burden and quality of life after 6 months. The present study extends these findings through a 12-month follow-up, aiming to evaluate the long-term effects of virtual care on glycaemic control, treatment satisfaction, and quality of life among young adults with type 1 diabetes.
methodsThis single-centre wait-list RCT included 70 young adults aged 18-25 years with type 1 diabetes in Stockholm, Sweden. Participants randomized to the intervention group had access to the virtual platform for 12 months whereas participants in the wait-list control group received access after 6 months. The platform facilitated real-time communication with healthcare providers. Glycated haemoglobin (HbA1c) levels, time in range, time below range, diabetes treatment satisfaction, and quality of life were assessed at baseline and at the 6- and 12-month follow-ups. Comparisons within and between groups were performed using Welch's paired and independent samples t-test, the Wilcoxon signed rank test, and the Mann-Whitney test.
resultsAt the 12-month follow-up, the intervention group showed a decreased HbA1c level from baseline (62.8 to 58.6 mmol/mol; P = 0.051) and improved time in range (46.6% to 56.9%; P = 0.002). In the wait-list control group, social burden decreased significantly from baseline to 12 months (4.3 to 0.03; P = 0.030). Other measures of quality of life, including social and emotional health, showed no significant differences.
conclusionsVirtual diabetes care may enhance engagement and modestly improve glycaemic control in young adults, serving as a practical complement to standard outpatient follow-up.
trial registrationISRCTN (ref: 73435627, registration date: 23/10/2019): https://doi.org/10.1186/ISRCTN73435627.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.